Cellectar Biosciences (CLRB)
(Delayed Data from NSDQ)
$3.07 USD
-0.17 (-5.25%)
Updated May 10, 2024 04:00 PM ET
After-Market: $3.07 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth A Momentum C VGM
Price, Consensus and EPS Surprise
CLRB 3.07 -0.17(-5.25%)
Will CLRB be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for CLRB based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for CLRB
Is Cellectar Biosciences (CLRB) Outperforming Other Medical Stocks This Year?
CLRB: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for CLRB
Cellectar Biosciences to Present at the Guggenheim Healthcare Talks Radiopharmaceuticals Day
Cellectar Biosciences to Announce First Quarter Financial Results and Host a Conference Call on Tuesday, May 14, 2024
Radiopharma stocks higher as sector welcomes the latest M&A deal
Cellectar Biosciences price target raised by $8 at Roth MKM, here's why
Analysts Conflicted on These Healthcare Names: Cellectar Biosciences (CLRB), MiMedx Group (MDXG) and Marinus (MRNS)